Sunday 18 October 2026
Export CTNM’s income statement to Excel — free account
Contineum Therapeutics, Inc.
CTNM Healthcare Biotechnology
Contineum Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $50.0 million. In the quarter to June 2026, EPS grew 35.5% and free cash flow grew 26.7%, each against the same quarter a year earlier.
7.02
0.88
−11.14%
Follow CTNM
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 12.33 | 3.35 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 22.00 | 15.25 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 31 | 41 | 51 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 1.61 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 50 | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | 100.00 | — | — | |||||
| EBT | — | — | — | — | — | — | (24) | 23 | (42) | (60) | |||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 46.34 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | (24) | 23 | (42) | (60) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 21.65 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | (10.81) | 1.24 | (2.18) | (2.17) | |||||
| Cash flow | — | — | — | — | — | — | (8.97) | 8.38 | (1.70) | (2.00) | |||||
| Capex | — | — | — | — | — | — | (0.05) | (0.18) | (0.03) | (0.01) | |||||
| Free cash flow | — | — | — | — | — | — | (9.02) | 8.20 | (1.72) | (2.01) | |||||
| Book value | — | — | — | — | — | — | (41.56) | (29.42) | 10.23 | 9.42 | |||||
| Shares, m | — | — | — | — | — | — | 2 | 2 | 19 | 28 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 1.83 | — | — | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | — | — | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | (5.03) | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (20) | 19 | (33) | (55) | ||||
| Capex | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | (20) | 19 | (33) | (56) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 41 | 122 | 196 | 258 | ||||
| Total debt | — | — | — | — | — | — | 4 | 0 | 1 | — | |||||
| Net debt | — | — | — | — | — | — | (43) | (125) | (203) | (263) | |||||
| Shareholders’ equity | — | — | — | — | — | — | (93) | (68) | 198 | 261 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | 3.48 | (24.62) | (24.51) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | 0.00 | (3.90) | (64.95) | (26.13) | |||||
Negative figures in brackets.
Fiscal years to Dec 2023 · latest quarter Jun 2023
Charts ten years each
Contineum Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings Inc. | $320.3M | — (loss-making) | — (loss-making) | −89.54% (below 0%: shrinking) | n/m | −245.65% (below 0%: shrinking) | 100.00% | (863.30%) | Compare |
| AGEN Agenus Inc. | $301.7M | 2.3× | 4.1× | +34.36% (above 0%: growing) | n/m | −55.25% (below 0%: shrinking) | 100.00% | 32.72% | Compare |
| CTNM Contineum Therapeutics, Inc. | $297.2M | — (loss-making) | — | — | n/m | +26.73% (above 0%: growing) | 100.00% | 0.00% | |
| ARTV Artiva Biotherapeutics, Inc. | $296.3M | — (loss-making) | — (loss-making) | — | n/m | +13.60% (above 0%: growing) | 100.00% | 0.00% | Compare |
| BNTC Benitec Biopharma Limited | $295.1M | — (loss-making) | — (loss-making) | −85.42% (below 0%: shrinking) | n/m | +38.90% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SRZN Surrozen, Inc. | $294.7M | — (loss-making) | — (loss-making) | +408.65% (above 0%: growing) | n/m | −21.25% (below 0%: shrinking) | 100.00% | (207.40%) | Compare |
| FULC Fulcrum Therapeutics, Inc. | $280.0M | — (loss-making) | — (loss-making) | +27,018.64% (above 0%: growing) | n/m | −13.05% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| OCGN Ocugen, Inc. | $275.9M | — (loss-making) | — (loss-making) | +8.38% (above 0%: growing) | n/m | −13.42% (below 0%: shrinking) | 100.00% | (1,105.11%) | Compare |
| NAUT Nautilus Biotechnology, Inc. | $274.9M | — (loss-making) | — | — | n/m | −3.16% (below 0%: shrinking) | 92.11% | (8,296.32%) | Compare |
| Median of peers | $294.9M | — | — | +21.37% | — | −13.24% | 100.00% | (103.70%) |
Contineum Therapeutics, Inc. (CTNM) key facts
- Contineum Therapeutics, Inc. (CTNM) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Contineum Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $50.0 million.
- As of October 16, 2026, CTNM traded at $7.02, a market capitalization of $297.2 million.
- Return on equity was −26.1% and debt-to-equity 0.00.
Contineum Therapeutics, Inc. (CTNM) Latest News
No news at this impact. Lower the threshold for more.